Iridex Revenues Drop 12 Percent in Q1-2017

May 12, 2017: By Jon Swedien

iridex-1x1Iridex reported May 3 that its Q1-2017 revenues totaled $10.5 million, a 12 percent decrease from Q1-2016 sales of $11.9 million.

The decline was primarily due to lower medical and surgical retinal product revenues, Iridex said. The Mountain View, California, company manufactures laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology.

“While our first quarter was marked by lower-than-expected financial results, we made significant progress towards the commercialization of the G6 platform,” said William Moore, Iridex president and CEO.

Iridex sold 64 Cyclo G6 laser systems in Q1-2017 and shipped approximately 6,600 single-use G6 probes. Iridex continues to anticipate sales of 400 to 450 G6 systems in 2017 but currently expects the number of G6 probes shipped to range from 35 thousand to 40 thousand, the company said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022